These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36511679)

  • 1. Prognostic significance of telomerase reverse transcriptase promoter gen mutations in high grade meningiomas.
    Cañas A; Jiménez E; Hakim F; Mejía JA; Ramón JF; Gómez D; Jaramillo-Velásquez D; Bermúdez S; Useche N; Pineda D; Cifuentes H; Becerra A; Muñoz Á; Santoyo N; Ruíz-Patiño A; Sotelo C; Archila P; Rodríguez J; Ávila J; Ordoñez-Reyes C; García-Robledo JE; Ricaurte L; Rojas L; Feo O; Burgos R; Ramírez C; Arrieta O; Zatarain-Barrón L; Vargas C; Carranza H; Otero J; Cardona AF
    Biomedica; 2022 Dec; 42(4):574-590. PubMed ID: 36511679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
    Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
    Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy and targeted therapies for meningiomas: what is the evidence?
    Graillon T; Tabouret E; Chinot O
    Curr Opin Neurol; 2021 Dec; 34(6):857-867. PubMed ID: 34629433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.
    Fürtjes G; Köchling M; Peetz-Dienhart S; Wagner A; Heß K; Hasselblatt M; Senner V; Stummer W; Paulus W; Brokinkel B
    J Neurooncol; 2016 Oct; 130(1):79-87. PubMed ID: 27465278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
    Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
    J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib.
    Cardona AF; Ruiz-Patiño A; Zatarain-Barrón ZL; Hakim F; Jiménez E; Mejía JA; Ramón JF; Useche N; Bermúdez S; Pineda D; Cifuentes H; Rojas L; Ricaurte L; Pino LE; Balaña C; Arrieta O
    PLoS One; 2019; 14(6):e0217340. PubMed ID: 31220093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
    Stögbauer L; Stummer W; Senner V; Brokinkel B
    Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort.
    Le Van T; Graillon T; Jacob J; Vauleon E; Feuvret L; Boch AL; Boetto J; Boone M; Bronnimann C; Caire F; De Barros A; Delaitre M; Di Stefano AL; Dore M; Ducray F; Dufour C; Engelhardt J; Fontaine D; Froelich S; Helleringer M; Huchet A; Joncour A; Jouanneau E; Mallereau CH; Monfilliette A; Le Fur E; Zemmoura I; Chinot O; Sanson M; Kalamarides M; Loiseau H; Peyre M
    J Neurooncol; 2021 May; 153(1):55-64. PubMed ID: 33778930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
    Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations in primary and secondary WHO grade III meningioma.
    Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
    Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas.
    Shin I; Park YW; Ahn SS; Kang SG; Chang JH; Kim SH; Lee SK
    J Neuroradiol; 2022 Jan; 49(1):59-65. PubMed ID: 33716047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of allelic losses and telomerase activity in meningiomas.
    Leuraud P; Dezamis E; Aguirre-Cruz L; Taillibert S; Lejeune J; Robin E; Mokhtari K; Boch AL; Cornu P; Delattre JY; Sanson M
    J Neurosurg; 2004 Feb; 100(2):303-9. PubMed ID: 15098535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
    Goutagny S; Nault JC; Mallet M; Henin D; Rossi JZ; Kalamarides M
    Brain Pathol; 2014 Mar; 24(2):184-9. PubMed ID: 24261697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
    Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
    Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
    Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
    J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional fractal dimension and lacunarity features may noninvasively predict TERT promoter mutation status in grade 2 meningiomas.
    Won SY; Lee JH; Lee N; Park YW; Ahn SS; Kim J; Chang JH; Kim SH; Lee SK
    PLoS One; 2022; 17(10):e0276342. PubMed ID: 36264940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas.
    Bettegowda C; Yip S; Jiang B; Wang WL; Clarke MJ; Lazary A; Gambarotti M; Zhang M; Sciubba DM; Wolinsky JP; Goodwin CR; McCarthy E; Germscheid NM; Sahgal A; Gokaslan ZL; Boriani S; Varga PP; Fisher CG; Rhines LD
    Neuro Oncol; 2019 Aug; 21(8):1005-1015. PubMed ID: 30976795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
    Furtner J; Schöpf V; Seystahl K; Le Rhun E; Rudà R; Roelcke U; Koeppen S; Berghoff AS; Marosi C; Clement P; Faedi M; Watts C; Wick W; Soffietti R; Weller M; Preusser M
    Neuro Oncol; 2016 Mar; 18(3):401-7. PubMed ID: 26354929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.